CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial design. He desribes looking for a partner, and what other cancers the therapy could have utility in. Plus, a next-generation bi-specific targeting CD40 and CEACAM5.
Fler avsnitt av BiotechTV - News
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
